The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights

Posted on by

New Spherix research highlights existing need for innovation in this underserved population EXTON, Pa., May 22, 2023 /PRNewswire/ — The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S. Despite the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.